Processing

Please wait...

Settings

Settings

Goto Application

1. WO2007089192 - PHARMACEUTICAL USE OF 2-HYDROXY-3- [5- (MORPHOLIN-4- YLMETHYL) PYRIDINE-2-YL] -1H- INDOLE-5-CARBONITRILE AS A FREE BASE OR SALTS

Publication Number WO/2007/089192
Publication Date 09.08.2007
International Application No. PCT/SE2007/000087
International Filing Date 31.01.2007
IPC
A61K 31/4439 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 19/08 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
08for bone diseases, e.g. rachitism, Paget's disease
A61P 19/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
08for bone diseases, e.g. rachitism, Paget's disease
10for osteoporosis
C07D 401/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
CPC
A61K 31/4439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 19/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
08for bone diseases, e.g. rachitism, Paget's disease
A61P 19/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
08for bone diseases, e.g. rachitism, Paget's disease
10for osteoporosis
Applicants
  • ASTRAZENECA AB [SE]/[SE] (AllExceptUS)
  • BERG, Anna-Lena [SE]/[SE] (UsOnly)
  • BHAT, Ratan [US]/[SE] (UsOnly)
Inventors
  • BERG, Anna-Lena
  • BHAT, Ratan
Agents
  • ASTRAZENECA AB
Priority Data
60/764,55102.02.2006US
60/777,34828.02.2006US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PHARMACEUTICAL USE OF 2-HYDROXY-3- [5- (MORPHOLIN-4- YLMETHYL) PYRIDINE-2-YL] -1H- INDOLE-5-CARBONITRILE AS A FREE BASE OR SALTS
(FR) UTILISATION PHARMACEUTIQUE DU 2-HYDROXY-3-[5-(MORPHOLIN-4-YLMÉTHYL)PYRIDINE-2-YL]-1H-INDOLE-5-CARBONITRILE COMME BASE LIBRE OU DE SELS
Abstract
(EN)
The present invention relates to a new use of 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile as a free base or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention and/or treatment of bone-related disorders, osteoporosis and increasing bone formation, bone mineral density. The present invention further relates to a method of prevention and/or treatment of these disorders or conditions.
(FR)
La présente invention concerne une nouvelle utilisation du 2-hydroxy-3-[5-(morpholin-4-ylméthyl)pyridin-2-yl]1H-indole-5-carbonitrile comme base libre, ou d'un sel pharmaceutiquement acceptable de ce dernier, dans la production d'un médicament servant à prévenir et/ou à traiter des troubles relatifs aux os, tels que l'ostéoporose, et à augmenter la formation osseuse ainsi que la densité minérale osseuse. Ladite invention se rapporte en outre à une méthode de prévention et/ou de traitement de ces troubles ou états pathologiques.
Latest bibliographic data on file with the International Bureau